Xena, I only follow biotech loosely these days, but at one time it was my main sector. One thing to know about the CNS sector is that it has generally been regarded as among the riskiest sectors to invest in within biotech. CNS was where I spent a lot of years (Cortex Pharma - AMPA receptor) but unfortunately with little to show for it. The only riskier area back then was 'gene therapy', which at the time was a brand new.
Your posts on Anavex have me curious, and also the mitochondrial aspect of the Cipro side effects. I'll have to get up to speed. Btw, Dr. Gundry had an entire book (2021) relating to mitochondrial function ('The Energy Paradox') with some interesting revelations on metabolic inflexibility, so it will be interesting to see if there is any potential overlap with your Cipro related condition.
Btw, one thing with Anavex, I can't say that I'm too enthralled with the CEO, based on first impressions anyway. He reminds me somewhat of the former CEO of Cytodyn, who is under investigation by the SEC. Just a vague resemblance though, on the 'vibe' scale. With a small cap bio the character of the CEO is extremely important, and so far with Missling I'm not getting a good vibe, although it's still early.
---
News 
Market Data 
Discover 
